Journal: Immunity

Article Title: Single-cell chromatin accessibility landscape identifies tissue repair program in human regulatory T cells

doi: 10.1016/j.immuni.2021.03.007

Figure Lengend Snippet:

Article Snippet: VioBright 515 anti-human PD-1 (CD279) , Miltenyi , AB_2752077.

Techniques: Purification, Control

Journal: Frontiers in Immunology

Article Title: Unveiling spatial complexity in solid tumor immune microenvironments through multiplexed imaging

doi: 10.3389/fimmu.2024.1383932

Figure Lengend Snippet: Immunophenotyping panel for multiplexed tissue imaging of cancer.

Article Snippet: PD-1 , REA1165 , 50 , 130-120-382 , PE , Miltenyi Biotec.

Techniques: Imaging

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Straightforward Generation of Ultrapure Off-the-Shelf Allogeneic CAR-T Cells

doi: 10.3389/fbioe.2020.00678

Figure Lengend Snippet: (A) CD62L/CD45RA expression in the CD8 population with (red) or without (blue) transfection of the anti-CD3 CAR mRNA. N=5; 5 independent T-cell donors. p-value: 0.2251 for CD45RA + CD62L + , 0.7472 for CD45RA + CD62L – , 0.2185 for CD45RA-CD62L – , and 0.2327 for CD45RA-CD62L + : (B) PD1 and LAG3 expression in the whole T-cell population with (red) or without (blue) transfection of the anti-CD3 CAR mRNA. N=5, 5 independent T-cell donors p-value: 0.1307 for PD1, 0.5295 for LAG3, 0.3597 for PD1/LAG3 and 0.7521 for double negatives. (C) Antigen-dependent proliferation of CAR T-cells with (red) or without (blue) transfection of the anti-CD3 CAR mRNA over a 10-day period. N=7; five independent T-cell donors. (D) Target cell killing over a period of 3 days. UCAR T-cells engineered with (red) or without (blue) transfection of the anti-CD3 CAR mRNA. N=3; three independent T-cell donors. Significance is determined by a standard unpaired t-test, * p ≤ 0.05, ** p ≤ 0.01.

Article Snippet: The proportion of T-cells expressing the CAR or different markers at their surface was then quantified using the following antibodies: anti-CD3 CAR [according to ( )]: Biotin-labeled polyclonal goat anti-mouse F(Ab’) 2 (Jackson Immunoresearch #115-065-07), streptavidin-APC (BD Bioscience #554067), CD3: Clone BW264/56, Vioblue (Miltenyi #130-094-363), TCRαβ: Clone REA652, PE (Miltenyi #130-109-920), CD4: Clone VIT4, PEVio770 (Miltenyi #130-096-552), CD8: Clone SK1, BV510 (Biolegend #344732), CD62L: Clone 145/15, APC (Miltenyi #130-113-617), CD45RA: Clone T6D11, Vioblue (Miltenyi #130-113-360), PD1: Clone REA1165, PE (Miltenyi #130-120-388) and LAG3: Clone 11C3C65, BV421 (Biolegend #369313).

Techniques: Expressing, Transfection

Journal: bioRxiv

Article Title: Pharmacologically modified pluripotent stem cell-based cancer vaccines with anti-metastatic potential

doi: 10.1101/2020.05.27.118471

Figure Lengend Snippet: (A) Tumor volumes in mice treated with VPA only, hESCs only, or hESCs+VPA (n=5-6). (B) Bioluminescence imaging by IVIS demonstrated the extent of the reduction in tumor areas in hESC+VPA-treated mice compared to the control group. On the left: the change over time in one mouse from each group. On the right: a comparison of tumors in different mice at day 44 post-challenge. (C) Comparison of tumor weights following surgical resection. (D) Direct bioluminescence imaging of surgically removed lungs (removed at day 44 post-challenge) revealed the reduction in metastastic load in mESC+VPA-treated mice compared to controls. (E) Bioluminescence imaging by IVIS revealed a significant decrease in lung metastasis in the hESC+VPA-treated group. (F) Measurements of total flux (photons/second; measured by IVIS) in surgically removed lungs had a significant positive correlation with tumor weight. (G) The frequency of CD4 + and CD8 + T cells was significantly higher in the tumors of hESC+VPA-treated mice than in other groups. (H) The frequency of CD4 + and CD8 + T cells in the spleen was significantly higher in the hESC+VPA-treated group compared to the control group. (I) PD-1 expression in CD4 + and CD8 + T cells was significantly lower in the hESC+VPA-treated group compared to the control group. (J) Dot plot images of flow cytometry results, showing high PD-1 expression by CD4 + T cells in the spleens of control mice, and reduced expression in the hESC+VPA group.

Article Snippet: They were then stained for cell surface markers using antibodies for CD44, CD24, CD45, CD8a, CD25, CD279 (PD-1), MHC class I (eBioscience), CD11b, Gr-1, CD3, CD4, CD279 (PD-1), CD45, CD44, and CD24 (Miltenyi Biotec).

Techniques: Imaging, Control, Comparison, Expressing, Flow Cytometry